Table 1.

Main inhibitors of mTOR and eIF4E

Target	Category	Compound	Clinical trials in ovarian cancer	Ref.
mTORC1	Antibiotic	Rapamycin		[54]
	Rapalogs	Temsirolimus	Completed	[45,46]
		Everolimus	Phase I/II	[47,48]
		Deferolimus		[49]
mTORC1 and mTORC2	Second generations inhibitors	Torin1		[55]
		INK128		[56]
		AZD8055		[57]
		AZD2014	Phase I/II	[58]
PI3K and mTOR	Dual inhibitors	PI-103		[59]
		NVP-BEZ235	Completed	[60]
		SF1126		[61]
		GNE-477		[62]
		XL765		[63]
eIF4E expression	Antisense oligonucleotides	ISIS 183750		[64]
		LY2275796		[65]
	miRNA	miR-768-3p		[66]
eIF4E phosphorylation	MEK inhibitor	U0126		[67]
	Small molecule	CGP57380		[68]
	Natural product	cercosporamide		[69]
eIF4E-partners interactions	Nucleoside analog	Ribavirin		[70-78]
	Small molecules	4Ei-1		[79,80]
		4EGI-1		[81,82]
		4E1RCat		[83]
	Oligopeptides	GnRH-4EBP fusion peptide		[84]
		4E-BP mimetics peptides		[85-87]